Most tools show you price and a P/E ratio. These are the signals that are harder to get, read straight from primary sources — SEC filings, government contract awards, lobbying disclosures, clinical trial registries, and short-interest data.
Companies are required to disclose bad news, and the disclosure is often the earliest public signal. We read item codes and form types directly, so these are exact rather than inferred:
Costly, legally disclosed, hard-to-fake actions by people who know the business: cluster buying by executives and directors, activist 13D crossings, Form 144 sale intentions filed before a sale completes, and shelf takedowns that dilute existing holders.
Federal contract awards and their momentum, lobbying activity, clinical trial phase and status for biotech, app-store rankings, developer activity, and search interest — each one a read on demand or progress that does not yet appear in reported financials.
Forward returns are measured sector-residualized, not absolute, so a signal is not credited for a sector-wide move. Each signal carries its own measured information coefficient with a sample size and a t-statistic, and a signal that has not yet accumulated enough evidence is labelled as still accumulating rather than presented as proven.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.